Premium
Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together
Author(s) -
Huang Fenglei,
Lasseter Kenneth C.,
Janssens Luc,
Verhaeghe Tom,
Lau Henry,
Zhao Qinying
Publication year - 2002
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270002042012005
Subject(s) - risperidone , galantamine , pharmacology , pharmacokinetics , active metabolite , crossover study , medicine , dopamine antagonist , bioavailability , drug interaction , drug , schizophrenia (object oriented programming) , antagonist , placebo , psychiatry , dementia , donepezil , receptor , alternative medicine , disease , pathology
To explore the steady‐state pharmacokinetic profile after coadministration of galantamine and risperidone, an open‐label, randomized, single‐center, two‐way crossover drug‐drug interaction study was conducted in 16 healthy elderly subjects, ages 60 years and older. The results showed that risperidone, when administered with galantamine, did not change the bioavailability of galantamine at steady state. In addition, systemic exposure of risperidone active moiety (risperidone plus 9‐hydroxyrisperidone), the most clinically relevant component of risperidone treatment, was not affected by galantamine coadministration, while systemic exposure was increased by approximately 10% for risperidone and decreased by about 10% for 9‐hydroxyrisperidone (active metabolite of risperidone). Galantamine and risperidone were both safe and well tolerated administered either alone or together. Thus, no dose adjustment for either risperidone or galantamine is necessary when these two drugs are administered together in the dose range evaluated.